::INDO AMERICAN JOURNAL OF PHARMACEUTICAL SCIENCES::

CODEN : IAJPBB
issn 2349-7750

News Updates Latest Volumes: COSMOS IMPACT FACTOR (2018)- 4.153, GLOBAL IMPACT FACTOR(2014) - 0.384, (2015) - 0.437, Indo American Journal of Pharmaceutical Sciences,

ResearcherID - CLICK HERE Scientific Journal Impact Factor (SJIF-2020) - CLICK HERE

TITLE:

THE PREVALENCE OF SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) IN PATIENTS OF HEPATITIS B AND C VIRUS ATTENDING SERVICES HOSPITAL

AUTHORS:

Dr. Sara Sikander, Dr. Fatima Arshad, Dr. Mah Mobeen Fatima

ABSTRACT:

Objective: The aim of our study was to find out prevalence of systemic lupus erythematosus (SLE) in patients of hepatitis B and C virus. Study design: A cross sectional study. Place and Duration: This study was conducted at Services Hospital Lahore for the duration of eight months starting from January, 2020 to September, 2020. Methodology: In the present study we include 39 diagnostic patients of systemic lupus erythematosus (SLE) of both genders. In these patients only those were included having documented diagnosis of SLE for at least 1 year or more with or without treatment. After this these cases were examined for their clinical and demographic characteristics and their blood samples were taken. We took 5ml of blood to test HBsAg for overall screening of antibodies of Hepatitis B and C. All the collected data was analyzed at SPSS software version 20. Results: According to the study we analyze 39 patients having systemic lupus erythematosus (SLE). The average duration of systemic lupus erythematosus (SLE) patients was 5.13±1.36 years and the average age of the systemic lupus erythematosus (SLE) patients was 27.13 ± 7.29. According to gender distribution the number of females were 87.18% (34) patients and the number of males were 12.82% (5) patients. 2.56% (1) case out of 39 cases had a history with pre-HBV infection and 7.69% (3) cases out of 39 had hepatitis C virus infection. HBsAg was overall screened for HCV antibodies and were found in 20.51% (8) patients and 7.69% (3) patients. Conclusion: At the end of our study, we concluded that SLE may play a role of protection against hepatitis B virus but not for hepatitis C virus infection. Moreover, experimental and epidemiological studies are essential to find out the role and mechanisms by which SLE affects hepatitis B and hepatitis C virus infections. Key words: Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Systemic Lupus Erythematosus (SLE)